Fibrinogen concentrate - Biotest AG

Drug Profile

Fibrinogen concentrate - Biotest AG

Alternative Names: BT-524

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotest AG
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Afibrinogenaemia

Most Recent Events

  • 04 Sep 2017 Phase-III clinical trials in Afibrinogenaemia in Spain (IV) (EudraCT2017-001163-20)
  • 01 Mar 2013 Phase-I/II clinical trials in Afibrinogenaemia in Italy (IV) (NCT02065882)
  • 31 Dec 2012 Preclinical trials in Afibrinogenaemia in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top